Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals both positive and negative aspects. On the positive side, there are significant cost reductions and potential regulatory advantages for ibezapolstat, supported by FDA designations. However, the company faces financial sustainability issues, with ongoing net losses and uncertainties in partnership timelines. The Q&A section showed management's cautious optimism but lacked concrete timelines or commitments, which could dampen investor confidence. Given these mixed signals, the stock is likely to remain stable in the short term, resulting in a neutral market reaction.
Key Financial Performance
Cash Balance $5.9 million as of September 30, 2025, compared to $3.7 million as of December 31, 2024, an increase due to $1.7 million raised through equity line of credit purchases and $1.4 million from a warrant exercise.
Research and Development Expenses (Q3) $0.4 million for the 3 months ended September 30, 2025, compared to $1.2 million for the same period in 2024, a decrease of $0.8 million due to lower manufacturing costs ($0.1 million) and consulting costs ($0.7 million).
Research and Development Expenses (9 months) $1.6 million for the 9 months ended September 30, 2025, compared to $4.6 million for the same period in 2024, a decrease of $3 million due to reductions in manufacturing costs ($0.7 million) and consulting costs ($2.3 million).
General and Administrative Expenses (Q3) $1.6 million for the 3 months ended September 30, 2025, consistent with the same period in 2024, with a $0.2 million decrease in compensation-related costs offset by a $0.1 million increase in legal fees.
General and Administrative Expenses (9 months) $4.9 million for the 9 months ended September 30, 2025, compared to $6.8 million for the same period in 2024, a decrease of $1.9 million due to reductions in professional fees ($0.6 million) and share-based compensation ($1.3 million).
Net Loss (Q3) $2 million or $1.23 per diluted share for the 3 months ended September 30, 2025, compared to $2.8 million or $3.45 per diluted share for the same period in 2024, a decrease due to lower R&D and consistent G&A expenses.
Net Loss (9 months) $6.4 million or $5.01 per diluted share for the 9 months ended September 30, 2025, compared to $11.3 million or $14.23 per share for the same period in 2024, a decrease due to lower R&D and G&A expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Ibezapolstat clinical trial updates: Presented new colonic-microbiome data showing microbiome-sparing properties and potential class effect of DNA pol IIIC inhibitors. Demonstrated sustained efficacy in Phase II trial for C. diff infection with no recurrence in cured patients.
Scientific collaboration publication: Published results in Nature Communications demonstrating ibezapolstat bound to its target, advancing the development of DNA pol IIIC inhibitors.
Patent expansion: Granted a new Australian patent for DNA polymerase IIIC inhibitors, adding to existing patents in the U.S., Israel, Japan, and India.
IDWeek presentation: Selected as one of five companies to present at IDWeek in Atlanta, showcasing new antimicrobials in the pipeline.
Nasdaq compliance: Regained compliance with Nasdaq listing requirements after a 1-for-20 reverse stock split and meeting equity thresholds.
Financial position: Ended Q3 2025 with $5.9 million in cash, up from $3.7 million at the end of 2024. Raised $1.7 million through equity line of credit and $1.4 million from warrant exercises.
Funding initiatives: Actively pursuing funding opportunities for Phase III clinical trials of ibezapolstat and exploring alternative pathways for success.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Compliance: The company recently regained compliance with Nasdaq listing requirements after a reverse stock split. However, maintaining compliance with Nasdaq's continued listing requirements remains a potential challenge.
Funding for Phase III Trials: The company is actively seeking funding opportunities for its Phase III clinical trial program for ibezapolstat. Lack of sufficient funding could delay or hinder the progress of these trials.
Macroeconomic Environment: The company acknowledges challenges in the macroeconomic environment, which could impact its operations and strategic objectives.
Competition in Antimicrobial Development: The company operates in a competitive sector, and the development of new antimicrobials by competitors could pose a risk to its market position.
Financial Sustainability: Despite raising additional funds, the company reported a net loss for the quarter and the year-to-date period, highlighting ongoing financial challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase III clinical trial funding: The company continues to identify and pursue funding opportunities for its Phase III clinical trial program for ibezapolstat, with several initiatives underway to achieve this goal.
Ibezapolstat's market potential: Ibezapolstat, if approved, could reduce the overall annual U.S. cost burden for C. diff infection, which is approximately $5 billion, with $2.8 billion attributed to recurrent infections.
Macroeconomic and industry challenges: The company remains confident in navigating through challenging macroeconomic conditions and industry-specific challenges while continuing the development of ibezapolstat.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you see increased potential for the FDA to prioritize domestically manufactured novel antibiotics under the current administration?
A:The company sees potential opportunities but is uncertain. They are already FDA Fast-Track and QIDP designated and are monitoring potential legislation for novel drugs treating life-threatening conditions. However, they are unsure if they will be the first antibiotic under such programs.
Q:What is your perspective on the PASTOR Act and its potential impact on the antibiotic funding landscape?
A:The management believes that the PASTOR Act and Project BioShield are not currently a focus in Washington due to fiscal uncertainties and the government shutdown. They expect these initiatives to be reconsidered once normalcy returns.
Q:Does the proposed clinical priority review voucher framework impact the company's regulatory approach or commercial strategy?
A:No, the company’s strategy remains the same. They are aware of the program and may utilize it at the appropriate time, but they are currently focused on Phase III trials and a 20-patient trial in the secondary C. diff market.
Q:Has the team explored filing for approval based solely on Phase IIb IBZ data?
A:No, they cannot file based solely on Phase IIb IBZ data due to the need for a safety database. Phase III trial data is required to meet FDA safety requirements.
Q:How do recent publications and presentations inform or change your clinical strategy ahead of Phase III?
A:The data reinforces confidence in their microbiome-sparing mechanism of action but does not change the clinical strategy. They plan to demonstrate their efficacy in the secondary C. diff market and aim to secure a public-private partnership.
Q:Can you provide a timeline for potential partnership discussions?
A:Management cannot provide a specific timeline as partnerships depend on mutual agreement. However, they anticipate major news by the next earnings call.
Q:Do QIDP and Fast-Track designations have time limits or requirements for continuation?
A:No, these designations are retained in perpetuity once granted.
Q:Are current operating expenses expected to remain steady?
A:Yes, operating expenses are expected to remain steady or decrease slightly due to ongoing cost-cutting measures. The company has $7 million in cash and $9 million remaining on their ELOC, allowing them to sustain operations while awaiting partnerships or M&A activity.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct timeline for partnership discussions, citing the dependency on mutual agreement. They also used vague language regarding the potential impact of the PASTOR Act and Project BioShield, attributing delays to fiscal uncertainties in Washington.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Corporate
Corporate Secretary
DNA pol
Founder President
Gram priority
Leiden University
Lillis Foundation
Medical Center
Nasdaq listing
Peggy Lillis
Secretary Director
State
addition
amendment
class effect
collaboration Leiden
compliance
compound
diff infection
exercise
listing rule
microbiome
pol IIIC
priority pathogen
requirement
share stock
stock split
stockholder
update ibezapolstat
warrant
work Peggy
ACXP Transcript
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights significant progress in clinical trials, a favorable FDA one-trial requirement, and an extended patent, all potentially reducing time to market and enhancing IP protection. Financials show reduced losses and prudent expense management. The Q&A reinforces confidence in trial strategies and FDA alignment. Although macroeconomic challenges exist, the overall sentiment is positive, suggesting a potential stock price increase in the short term, especially if the market recognizes the strategic advancements and financial discipline.
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture: significant cost reductions and decreased net losses are positive, but there's uncertainty in trial timelines and management's vague responses in the Q&A. While financial health has improved, the lack of clear guidance and potential delays in trials temper optimism. The absence of a market cap makes it difficult to gauge stock volatility, suggesting a neutral sentiment with a potential slight positive shift if trial developments progress smoothly.
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reveals both positive and negative aspects. On the positive side, there are significant cost reductions and potential regulatory advantages for ibezapolstat, supported by FDA designations. However, the company faces financial sustainability issues, with ongoing net losses and uncertainties in partnership timelines. The Q&A section showed management's cautious optimism but lacked concrete timelines or commitments, which could dampen investor confidence. Given these mixed signals, the stock is likely to remain stable in the short term, resulting in a neutral market reaction.
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture: financial performance shows improvement with reduced losses and expenses, yet funding challenges and macroeconomic conditions pose risks. Despite positive regulatory guidance and potential partnerships, the lack of specific feedback from the medical community and operational cost concerns temper optimism. The neutral sentiment reflects these balanced factors, with no clear catalyst for a strong price movement.
ACXP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
